MARKSANS PHARMA LTD. - 524404 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of related party transactions of the Company and its subsidiaries for the half year ended 31st March, 2022. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q4 &FY22 Earnings Conference Call held on June 1, 2022.
Buy Marksans Pharma; target of Rs 80: Arihant Capital
Arihant Capital is bullish on Marksans Pharma has recommended buy rating on the stock with a target price of Rs 80 in its research report dated June 06, 2022. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for schedule of conference call with Nirmal Bang Institutional Equities Investor.
Earnings Call for Q4FY22 of Marksans Pharma
Conference Call with Marksans Pharma Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Q4&FY22 Results Conference Call is hosted on the website of the Company at http://marksanspharma.com/investors-meet.html MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022 published today i.e. 1st June, 2022 in the Business Standard (English) and Tarun Bharat (Marathi) newspapers. MARKSANS PHARMA LTD. - 524404 - Board recommends Final Dividend
Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2022, inter alia, has recommended final dividend @ Re. 0.25 (Rupee Zero and Paise Twenty Five) i.e. 25% per equity share of Re. 1/- each face value for the financial year ended March 31, 2022, subject to approval of the shareholders in the ensuing Annual General Meeting. Q4FY22 Quarterly Result Announced for Marksans Pharma Ltd.
Marksans Pharma declares Q4FY22 result: Q4FY22 Operating revenue was Rs 418.0 cr. compared to Rs 330.2 cr. in Q4FY21, an increase of +26.6% YoY Gross profit was Rs 206.4 cr., with gross margin at 49.4% EBITDA was Rs 63.6 cr., with EBITDA margin at 15.2% PBT was Rs 52.6 cr., while PAT stood at Rs 29.7 cr. FY22 Operating revenue increased by 8.3% YoY to Rs 1,490.8 cr. Gross profit was Rs 774.0 cr., with gross margin at 51.9% EBITDA was Rs 258.9 cr. with EBITDA Margin at 17.4%. EBITDA was impacted by: Higher base effect of FY21 due to Covid19 driven panic buying and uncertainty input cost pressures seen during the year on account of increased freight costs and geopolitical tensions Persistent pricing pressure of high single digit in US seen during the year impacting generic Rx business PBT was Rs 247.5 cr., while PAT stood at Rs 186.8 cr. Generated Cash from Operations and Free Cash Flow of Rs 99.3 cr. and Rs 52.3 cr. respectively Total R&D; Expenditure was Rs 30.2 cr., constituting ~2% of revenue and expected to increase to ~4-5% over the next few years Capex incurred was Rs 46.3cr. Plan to incur capex of Rs 200.0 cr. over two years for increasing manufacturing capacities Working capital cycle was ~108 days Expanded in existing markets with the launch of 12 new products in UK/ Europe markets and 3 new products in USA Result PDF